Open AccessROS1-dependent cancers — biology, diagnostics and therapeutics
Author(s) -
Alexander Drilon,
Chelsea Jenkins,
Sudarshan R. Iyer,
Adam J. Schoenfeld,
Clare Keddy,
Monika A. Davare
Publication year - 2020
Publication title -
nature reviews. clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.214
H-Index - 155
eISSN - 1759-4782
pISSN - 1759-4774
DOI - 10.1038/s41571-020-0408-9
Subject(s) - ros1 , medicine , tyrosine kinase , cancer research , receptor tyrosine kinase , kinase , targeted therapy , cancer , pharmacology , computational biology , adenocarcinoma , biology , receptor , genetics
The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown physiological role in humans. Somatic chromosomal fusions involving ROS1 produce chimeric oncoproteins that drive a diverse range of cancers in adult and paediatric patients. ROS1-directed tyrosine kinase inhibitors (TKIs) are therapeutically active against these cancers, although only early-generation multikinase inhibitors have been granted regulatory approval, specifically for the treatment of ROS1 fusion-positive non-small-cell lung cancers; histology-agnostic approvals have yet to be granted. Intrinsic or extrinsic mechanisms of resistance to ROS1 TKIs can emerge in patients. Potential factors that influence resistance acquisition include the subcellular localization of the particular ROS1 oncoprotein and the TKI properties such as the preferential kinase conformation engaged and the spectrum of targets beyond ROS1. Importantly, the polyclonal nature of resistance remains underexplored. Higher-affinity next-generation ROS1 TKIs developed to have improved intracranial activity and to mitigate ROS1-intrinsic resistance mechanisms have demonstrated clinical efficacy in these regards, thus highlighting the utility of sequential ROS1 TKI therapy. Selective ROS1 inhibitors have yet to be developed, and thus the specific adverse effects of ROS1 inhibition cannot be deconvoluted from the toxicity profiles of the available multikinase inhibitors. Herein, we discuss the non-malignant and malignant biology of ROS1, the diagnostic challenges that ROS1 fusions present and the strategies to target ROS1 fusion proteins in both treatment-naive and acquired-resistance settings.